Paul Kim Sells 10,299 Shares of Fulgent Genetics, Inc. (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) CFO Paul Kim sold 10,299 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $33.62, for a total value of $346,252.38. Following the transaction, the chief financial officer now owns 215,553 shares in the company, valued at $7,246,891.86. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Paul Kim also recently made the following trade(s):

• On Thursday, August 17th, Paul Kim sold 1,798 shares of Fulgent Genetics stock. The stock was sold at an average price of $33.88, for a total value of $60,916.24.
• On Friday, June 2nd, Paul Kim sold 1,403 shares of Fulgent Genetics stock. The shares were sold at an average price of $40.30, for a total transaction of $56,540.90.

Fulgent Genetics Stock Down 2.4 %

Shares of NASDAQ FLGT opened at $32.76 on Friday. The firm has a market cap of $980.51 million, a price-to-earnings ratio of -19.98 and a beta of 1.46. Fulgent Genetics, Inc. has a 52-week low of $28.27 and a 52-week high of $46.14. The business’s 50 day moving average is $36.51 and its two-hundred day moving average is $34.61.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings results on Friday, August 4th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.26. The business had revenue of $67.85 million during the quarter, compared to the consensus estimate of $62.68 million. Fulgent Genetics had a negative net margin of 15.84% and a negative return on equity of 3.29%. Analysts anticipate that Fulgent Genetics, Inc. will post -2.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on FLGT. Piper Sandler lifted their price target on shares of Fulgent Genetics from $35.00 to $37.00 in a research report on Monday, May 8th. StockNews.com started coverage on Fulgent Genetics in a research report on Thursday, August 17th. They issued a “hold” rating on the stock.

Hedge Funds Weigh In On Fulgent Genetics

Several institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its stake in shares of Fulgent Genetics by 3.4% in the first quarter. BlackRock Inc. now owns 3,646,420 shares of the company’s stock worth $113,841,000 after acquiring an additional 118,638 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Fulgent Genetics by 2.4% in the third quarter. Vanguard Group Inc. now owns 1,365,736 shares of the company’s stock worth $52,062,000 after acquiring an additional 32,173 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Fulgent Genetics by 22.6% in the second quarter. Dimensional Fund Advisors LP now owns 1,046,481 shares of the company’s stock worth $38,752,000 after acquiring an additional 192,932 shares in the last quarter. State Street Corp grew its stake in shares of Fulgent Genetics by 5.3% during the third quarter. State Street Corp now owns 756,357 shares of the company’s stock worth $28,832,000 after purchasing an additional 38,121 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of Fulgent Genetics by 82.9% during the second quarter. Nuveen Asset Management LLC now owns 413,457 shares of the company’s stock worth $15,310,000 after purchasing an additional 187,404 shares in the last quarter. Institutional investors and hedge funds own 46.09% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc, together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests.